Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03369106
Active, not recruiting Observational

Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study

NCT03369106 · tracked via the Priya Life Science France tracker
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Phase
Observational
Started
2018-02-06
Last updated
2026-03-11

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

Composite severity score calculation

Composite severity score calculation: Neurological examination, cognitive testing, and MRI exam

Study summary

This study will identify a combination of disease severity markers (genetic, immunology, epigenetic, imaging) associated with disease severity and progression in a cohort of patients with multiple sclerosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinically isolated syndrome or Multiple sclerosis (2010 Mc Donald criteria) * Sibling having Clinically isolated syndrome or Multiple sclerosis (2010 Mc Donald criteria) willing to participate to the study * Affiliated to the French social security or equivalent Exclusion Criteria: * Cyclophosphamide, mitoxantrone or methylprednisolone infusion within one month before inclusion * Multiple sclerosis relapse within one month before inclusion * Concomitant severe or uncontrolled disease

Primary outcome measure(s)

  • Change of Expanded Disability Status Scale (EDSS) — Baseline and 18 months
    Change in the Expanded Disability Status Scale (EDSS) which is the neurological assessment of disability related to multiple sclerosis. The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.

Trial sites (1)

FacilityCityRegionStatus
CIC Neurosciences Institut du Cerveau et de la Moelle Epinière Paris France

More Institut National de la Santé Et de la Recherche Médicale, France trials in France

French Childhood Cancer Survivor Study Recruiting
Neural Correlates of Movement Disorders Associated With PRRT2 Related Paroxysmal Kinesigenic Dyskinesia - an Ancillary Study of AMEDYST Research Recruiting
Validation and Implementation of 3T MRI Research Protocols Recruiting
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms Recruiting
Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans Recruiting

Other trials for the same condition

Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome Recruiting
EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis Recruiting
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis Active, not recruiting
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. Recruiting
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03369106 on ClinicalTrials.gov ↗ ← All trials in France